In a groundbreaking study published this year, 2024, in the Journal of Alzheimer's Disease, researchers have presented compelling evidence that sildenafil, commonly known by its brand name Viagra and used for the treatment of erectile dysfunction, may also offer protective benefits against Alzheimer’s disease. Spearheaded by Feixiong Cheng, PhD, director of the Cleveland Clinic Genome Center, the study leverages extensive real-world patient data analysis alongside advanced mechanistic studies to suggest a new potential use for this well-known medication. This is a link that many have spoken about but few evidence has been shown... until now.
The study meticulously analyzed patient data from two significant databases, the MarketScan Medicare Supplemental database spanning from 2012 to 2017 and the Clinformatics database from 2007 to 2020. By employing propensity score-stratified analyses, which were carefully adjusted for gender, age, race, and existing comorbidities, the researchers sought to understand the impact of sildenafil use on Alzheimer's prevalence and incidence.
Their findings were revealing. Patients who took sildenafil exhibited a 30% to 54% reduced prevalence of Alzheimer's disease compared to those who did not use the drug, even after adjusting for potential confounding factors. Specifically, sildenafil use was associated with a 54% reduced incidence of AD in the MarketScan database and a 30% reduced prevalence of AD in the Clinformatics database when compared with users of spironolactone, one of the control drugs studied.
To delve deeper into the potential mechanisms behind sildenafil's protective effects against Alzheimer's, the team conducted experiments on neurons derived from induced pluripotent stem cells (iPSC) of AD patients. These cells, both from familial and sporadic cases of Alzheimer's, showed a significant reduction in tau hyperphosphorylation—a hallmark of Alzheimer’s pathology—when treated with sildenafil in a dose-dependent manner.
Further bolstering their hypothesis, RNA-sequencing data analysis of these sildenafil-treated neurons revealed that the drug specifically targets genes and pathobiological pathways associated with Alzheimer's, providing a mechanistic basis for its beneficial effects.
While previous studies have hinted at the potential protective effects of phosphodiesterase type 5 inhibitors (PDE5i), such as sildenafil, on Alzheimer's risk, the research community has seen some debate, highlighted by a study in Brain Communications in late 2022 that found no link between ED medications and reduced Alzheimer's risk. Despite these conflicting reports, the comprehensive approach and findings of the current study add significant weight to the argument for repurposing sildenafil as a treatment option for Alzheimer's.
Dr. Cheng's team utilized artificial intelligence to integrate data across multiple domains, underscoring sildenafil's promise against this devastating neurological disease. "Our findings provide further weight to repurposing this existing FDA-approved drug as a novel treatment for Alzheimer's, which is in great need of new therapies," stated Cheng in a recent news release.
With these promising results, the research team believes there is a strong case for conducting clinical trials to further explore sildenafil's effectiveness in patients with Alzheimer's disease. As the global community continues to seek new therapies for Alzheimer’s—a disease that affects millions worldwide—the potential repurposing of sildenafil represents a hopeful avenue of investigation, potentially offering a new beacon of hope for patients and their families.
